Suven Life Sciences Ltd has announced that two product patents were granted in Mexico and Korea for two of their new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2023.

These granted patents are exclusive intellectual property of Suven and are achieved through the exclusive internal discovery research efforts. Products out of these inventories which are in Pre-clinical development may be out-licensed at the stage of clinical phase-I or Phase II stage.

“We are very pleased by the issuance of these patents to Suven for our drug candidates that are being developed for CNS disorders which targets an $ 18 billion potential market opportunity globally” says Venkat Jasti CEO the Company.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like attention deficient hyperactivity, Alzheimer’s Parkinson, Schizophrenia and Huntington’s.

Suven Life Sciences is a biopharmaceutical Company focused on discovering, developing and commercializing novel pharmaceutical Products, which are first in class or best in class therapies through the use of GPCR targets. The Company has six internally-discovered therapeutic drug candidates currently, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease. Parkinson’s disease and obesity are in addition to developmental candidates in Alzheimer’s disease and Schizophrenia.